| Literature DB >> 27734935 |
Hailong Song1,2,3, Yuan Lu4,5, Zhe Qu1,2,3, Valeri V Mossine4, Matthew B Martin4, Jie Hou3,6, Jiankun Cui1,2,3, Brenda A Peculis4, Thomas P Mawhinney4, Jianlin Cheng3,6, C Michael Greenlief3,7, Kevin Fritsche3,8, Francis J Schmidt4, Ronald B Walter5, Dennis B Lubahn3,4, Grace Y Sun1,2,3,4, Zezong Gu1,2,3.
Abstract
Aged garlic extract (AGE) is widely used as a dietary supplement on account of its protective effects against oxidative stress and inflammation. But less is known about specific molecular targets of AGE and its bioactive components, including N-α-(1-deoxy-D-fructos-1-yl)-L-arginine (FruArg). Our recent study showed that both AGE and FruArg significantly attenuate lipopolysaccharide (LPS)-induced neuroinflammatory responses in BV-2 microglial cells. This study aims to unveil effects of AGE and FruArg on gene expression regulation in LPS stimulated BV-2 cells. Results showed that LPS treatment significantly altered mRNA levels from 2563 genes. AGE reversed 67% of the transcriptome alteration induced by LPS, whereas FruArg accounted for the protective effect by reversing expression levels of 55% of genes altered by LPS. Key pro-inflammatory canonical pathways induced by the LPS stimulation included toll-like receptor signaling, IL-6 signaling, and Nrf2-mediated oxidative stress pathway, along with elevated expression levels of genes, such as Il6, Cd14, Casp3, Nfkb1, Hmox1, and Tnf. These effects could be modulated by treatment with both AGE and FruArg. These findings suggests that AGE and FruArg are capable of alleviating oxidative stress and neuroinflammatory responses stimulated by LPS in BV-2 cells.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27734935 PMCID: PMC5062119 DOI: 10.1038/srep35323
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1LPS induced gene changes in BV-2 microglial cells.
LPS treatment induced differential expression of 2563 genes. For a gene to be considered as differentially expressed gene, the “log2Fold Change” has to ≥1 or ≤−1, with a FDR adjusted p-value ≤ 0.05. Red region highlighted up-regulated genes (1391 genes), green region highlighted down-regulated genes (1172 genes). Vertical redline represented p-adj = 0.05, two horizontal lines indicate log2Fold Change of +1 and −1.
Figure 2Effects of LPS in BV-2 microglial cells on top canonical pathways and disease/function networks.
(A) Top 10 canonical pathways predicted by the differentially expressed genes corresponding to LPS stimulation of BV-2 cells. The canonical pathways were ranked according to the –log (p-value). A ratio indicates the numbers of genes that were differentially expressed in each pathway over the total numbers of genes in that specific pathway. (B) The top disease and function network is associated with cell cycle, cellular development, and cellular growth and proliferation corresponding to the LPS stimulation of BV-2 cells. The identified genes involved in the networks were displayed in red (up-regulation) and green (down-regulation) color. The color intensity indicates the degree of regulation. Solid lines in the network imply direct interactions between genes, and dashed lines indicate indirect interactions. Geometric shapes represent different general functional families of gene regulation (diamond for enzyme, oval for transcription regulator, trapezoid for transporter, inverted triangle for kinase, double circle for complex/group, and circle for others).
Figure 3AGE and FruArg repress LPS-induced alteration of gene expression in BV-2 cells.
(A,B) Venn graph and heatmap showing AGE co-treatment with LPS stimulation was capable of repressing LPS-altered genes (LPS+/−). A large portion of AGE co-treatment down-regulated genes (AGE_LPS-) were up-regulated by LPS; similarly, a large portion of AGE co-treatment up-regulated genes (AGE_LPS+) were down-regulated by LPS treatment alone. Similar effect as AGE was also observed after FruArg treatment (FruArg_LPS+/−). In addition, there are 80 genes that were found to have the same LPS repressing activity after AGE or FruArg treatment. (C) Principle component analysis showed that these 80 genes effectively separated untreated control (UNT) from LPS stimulus, as well as co-treatment of LPS with either AGE or FruArg.
Summary of PCA.
| Importance of components | PC1 | PC2 | PC3 | PC4 | PC5 | PC6 | PC7 | PC8 |
|---|---|---|---|---|---|---|---|---|
| Standard deviation | 15.32700 | 5.10028 | 4.56230 | 1.83078 | 1.30763 | 0.98858 | 0.70489 | 2.628E−15 |
| Proportion of Variance | 0.81490 | 0.09023 | 0.07220 | 0.01163 | 0.00593 | 0.00339 | 0.00172 | 0.000E + 00 |
| Cumulative Proportion | 0.81490 | 0.90513 | 0.97730 | 0.98895 | 0.99489 | 0.99828 | 1.00000 | 1.000E + 00 |
Principal components were ranked based on the proportion of variance they accounted in the dataset. The first 3 PCs accounted for most of the variance of the dataset.
Figure 4Effects of AGE on LPS-induced alterations of canonical pathways and disease/function networks in BV-2 microglial cells.
(A) Top 10 canonical pathways affected by LPS stimulation were repressed by AGE treatment. (B) The top disease and function network is associated with antimicrobial response, inflammatory response, and infectious diseases corresponding to the effects of AGE on LPS stimulation of BV-2 cells.
Figure 5Effects of FruArg on LPS-induced alterations of canonical pathways and disease/function networks in BV-2 microglial cells.
(A) Top 10 canonical pathways predicted by the differentially expressed genes corresponding to the effects of FruArg on LPS induction of BV-2 cells. (B) The top disease and function network is associated with cellular movement, cell death and survival, and cell morphology corresponding to the effects of FruArg on LPS stimulation of BV-2 cells.